149 related articles for article (PubMed ID: 23944386)
1. Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents.
Leivers AL; Tallant M; Shotwell JB; Dickerson S; Leivers MR; McDonald OB; Gobel J; Creech KL; Strum SL; Mathis A; Rogers S; Moore CB; Botyanszki J
J Med Chem; 2014 Mar; 57(5):2091-106. PubMed ID: 23944386
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity.
Bianco A; Reghellin V; Donnici L; Fenu S; Alvarez R; Baruffa C; Peri F; Pagani M; Abrignani S; Neddermann P; De Francesco R
PLoS Pathog; 2012; 8(3):e1002576. PubMed ID: 22412376
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C Virus Subverts Human Choline Kinase-α To Bridge Phosphatidylinositol-4-Kinase IIIα (PI4KIIIα) and NS5A and Upregulates PI4KIIIα Activation, Thereby Promoting the Translocation of the Ternary Complex to the Endoplasmic Reticulum for Viral Replication.
Wong MT; Chen SS
J Virol; 2017 Aug; 91(16):. PubMed ID: 28566381
[TBL] [Abstract][Full Text] [Related]
4. NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.
Reghellin V; Donnici L; Fenu S; Berno V; Calabrese V; Pagani M; Abrignani S; Peri F; De Francesco R; Neddermann P
Antimicrob Agents Chemother; 2014 Dec; 58(12):7128-40. PubMed ID: 25224012
[TBL] [Abstract][Full Text] [Related]
5. Mapping of functional domains of the lipid kinase phosphatidylinositol 4-kinase type III alpha involved in enzymatic activity and hepatitis C virus replication.
Harak C; Radujkovic D; Taveneau C; Reiss S; Klein R; Bressanelli S; Lohmann V
J Virol; 2014 Sep; 88(17):9909-26. PubMed ID: 24920820
[TBL] [Abstract][Full Text] [Related]
6. The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A.
Reiss S; Harak C; Romero-Brey I; Radujkovic D; Klein R; Ruggieri A; Rebhan I; Bartenschlager R; Lohmann V
PLoS Pathog; 2013 May; 9(5):e1003359. PubMed ID: 23675303
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.
Vaillancourt FH; Brault M; Pilote L; Uyttersprot N; Gaillard ET; Stoltz JH; Knight BL; Pantages L; McFarland M; Breitfelder S; Chiu TT; Mahrouche L; Faucher AM; Cartier M; Cordingley MG; Bethell RC; Jiang H; White PW; Kukolj G
J Virol; 2012 Nov; 86(21):11595-607. PubMed ID: 22896614
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation.
Lim YS; Hwang SB
J Biol Chem; 2011 Apr; 286(13):11290-8. PubMed ID: 21297162
[TBL] [Abstract][Full Text] [Related]
9. PI4KIII inhibitor enviroxime impedes the replication of the hepatitis C virus by inhibiting PI3 kinases.
Delang L; Harak C; Benkheil M; Khan H; Leyssen P; Andrews M; Lohmann V; Neyts J
J Antimicrob Chemother; 2018 Dec; 73(12):3375-3384. PubMed ID: 30219827
[TBL] [Abstract][Full Text] [Related]
10. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment.
Reiss S; Rebhan I; Backes P; Romero-Brey I; Erfle H; Matula P; Kaderali L; Poenisch M; Blankenburg H; Hiet MS; Longerich T; Diehl S; Ramirez F; Balla T; Rohr K; Kaul A; Bühler S; Pepperkok R; Lengauer T; Albrecht M; Eils R; Schirmacher P; Lohmann V; Bartenschlager R
Cell Host Microbe; 2011 Jan; 9(1):32-45. PubMed ID: 21238945
[TBL] [Abstract][Full Text] [Related]
11. Suppression of hepatitis C virus replication by cyclin-dependent kinase inhibitors.
Munakata T; Inada M; Tokunaga Y; Wakita T; Kohara M; Nomoto A
Antiviral Res; 2014 Aug; 108():79-87. PubMed ID: 24893207
[TBL] [Abstract][Full Text] [Related]
12. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening.
Trotard M; Lepère-Douard C; Régeard M; Piquet-Pellorce C; Lavillette D; Cosset FL; Gripon P; Le Seyec J
FASEB J; 2009 Nov; 23(11):3780-9. PubMed ID: 19608626
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibitors of hepatitis C virus replication.
Neyts J
Antiviral Res; 2006 Sep; 71(2-3):363-71. PubMed ID: 16843538
[TBL] [Abstract][Full Text] [Related]
14. Roles of phosphoinositides and phosphoinositides kinases in hepatitis C virus RNA replication.
Lee C
Arch Pharm Res; 2012 Oct; 35(10):1701-11. PubMed ID: 23139120
[TBL] [Abstract][Full Text] [Related]
15. Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells.
Frentzen A; Anggakusuma ; Gürlevik E; Hueging K; Knocke S; Ginkel C; Brown RJ; Heim M; Dill MT; Kröger A; Kalinke U; Kaderali L; Kuehnel F; Pietschmann T
Hepatology; 2014 Jan; 59(1):78-88. PubMed ID: 23873628
[TBL] [Abstract][Full Text] [Related]
16. Modulation of hepatitis C virus genome replication by glycosphingolipids and four-phosphate adaptor protein 2.
Khan I; Katikaneni DS; Han Q; Sanchez-Felipe L; Hanada K; Ambrose RL; Mackenzie JM; Konan KV
J Virol; 2014 Nov; 88(21):12276-95. PubMed ID: 25122779
[TBL] [Abstract][Full Text] [Related]
17. Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.
Chatterji U; Bobardt M; Tai A; Wood M; Gallay PA
Antimicrob Agents Chemother; 2015 May; 59(5):2496-507. PubMed ID: 25666154
[TBL] [Abstract][Full Text] [Related]
18. Development of a high-content screening assay to identify compounds interfering with the formation of the hepatitis C virus replication complex.
Berke JM; Fenistein D; Pauwels F; Bobbaers R; Lenz O; Lin TI; Krausz E; Fanning G
J Virol Methods; 2010 May; 165(2):268-76. PubMed ID: 20153373
[TBL] [Abstract][Full Text] [Related]
19. 2-Alkyloxazoles as potent and selective PI4KIIIβ inhibitors demonstrating inhibition of HCV replication.
Keaney EP; Connolly M; Dobler M; Karki R; Honda A; Sokup S; Karur S; Britt S; Patnaik A; Raman P; Hamann LG; Wiedmann B; LaMarche MJ
Bioorg Med Chem Lett; 2014 Aug; 24(16):3714-8. PubMed ID: 25065492
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
Zhang X; Zhang N; Chen G; Turpoff A; Ren H; Takasugi J; Morrill C; Zhu J; Li C; Lennox W; Paget S; Liu Y; Almstead N; Njoroge FG; Gu Z; Komatsu T; Clausen V; Espiritu C; Graci J; Colacino J; Lahser F; Risher N; Weetall M; Nomeir A; Karp GM
Bioorg Med Chem Lett; 2013 Jul; 23(13):3947-53. PubMed ID: 23683597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
